<DOC>
	<DOCNO>NCT00809185</DOCNO>
	<brief_summary>RATIONALE : RAD001 ( Everolimus ) may stop growth cancer cell block enzyme need growth block blood flow cancer . PURPOSE : This phase II trial study well RAD001 ( everolimus ) work treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>RAD001 ( Everolimus ) Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical activity ( improvement erythroid response and/or improvement cytopenia , bone marrow morphology/cytogenetics ) RAD001 ( everolimus ) patient low intermediate-1 risk myelodysplastic syndrome . - Assess toxicity drug patient . Secondary - Examine laboratory correlate ( S6K1 level , angiogenesis pre- post-treatment ) determine correlate correspond dose clinical activity RAD001 ( everolimus ) . - Evaluate presence HLA-DR15 cytotoxic T-cell population patient pre- post-treatment correlate response treatment . - Examine incidence null GSTT-1 phenotype myelodysplastic syndrome patient correlate response RAD001 ( everolimus ) . OUTLINE : Patients receive oral RAD001 ( everolimus ) daily day 1-21 . Courses repeat every 28 day absence disease progression relapse . Blood sample collect periodically study . Samples analyze S6K1 activity , effector T cell flow cytometry , GSTT-1 PCR , HLA-DR15 level .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Low intermediate1 risk myelodysplastic syndrome International Prognostic Scoring System ( IPSS ) criterion IPSS score &lt; 1.5 Requiring transfusion 2 unit red blood cell least month ( four week prior accrual study ) High level endogenous epoetin alfa ( i.e. , &gt; 200 mU/mL ) Unlikely respond epoetin alfa , document clinical nonresponse epoetin alfa ( dose ≥ 40,000 U weekly ) darbepoetin alfa ( dose &gt; 200 mcg every week ) ( i.e. , &lt; 2 g/dL increase hemoglobin decrease transfusion requirement least 4 week treatment ) No chronic myelomonocytic leukemia PATIENT CHARACTERISTICS : ECOG Performance Status 02 Liver enzyme ( AST ALT ) total bilirubin ≤ 2 time upper limit normal Serum creatinine ≤ 2 time upper limit normal No clinically significant anemia due iron , B12 , folate deficiency ; autoimmune hereditary hemolysis ; gastrointestinal bleeding Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious poorly control medical condition could exacerbate complicate compliance study therapy PRIOR CONCURRENT THERAPY : At least 4 week since prior treatment ( include growth factor ) No chronic use ( &gt; 2 week ) physiologic dos corticosteroid agent ( dose equivalent &gt; 10 mg/day prednisone ) within 28 day first day study drug No concurrent use another investigational agent No concurrent therapy cytotoxic drug , steroid , growth factor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
</DOC>